摘要
目的 评价中间型人工肝支持方法血浆置换对重型肝炎肝功能的支持效果和安全性。方法 对 17例重型肝炎患者进行血浆置换治疗 ,观察治疗前后患者临床症状、体征变化 ,比较治疗前后肝、肾功能 ,血常规 ,凝血酶原时间 (PT)和凝血酶原活动度 (PTa)变化。结果 血浆置换治疗后 ,患者的临床症状均有不同程度改善 ,总有效率为 5 8.8% ,最终存活率仅为 11.8%。检测指标中转氨酶、总胆红素、凝血酶原时间、凝血酶原活动度和总蛋白治疗前后差异均有显著性 (P<0 .0 5或 P<0 .0 1) ;血尿素氮、血肌酐和血常规各指标治疗前后差异均无显著性 (P均 >0 .0 5 ) ;而且不良反应较轻。结论 中间型人工肝对重型肝炎患者肝功能有肯定的支持效果。
Objective To evaluate the clinical efficacy and safety of middle mode artificial liver-plasma pheresis in treatment of severe hepatitis. Methods Seventeen patients with severe hepatitis were treated with plasma pheresis. The results of liver function, renal function, blood routine, prothrombin time (PT), prothrombin time activity (PTa) before and after the treatment were analyzed. All patients were observed closely. Results Symptoms of patients treated with plasma pheresis were improved, and the total effective rate reached 58.8 %, but the survival rate was only 11.8 %. Compared with those before the therapy, there were significant differences in aminotransferase, total bilirubin, direct bilirubin, PT, PTa and total protein level after treatment(P<0.05 or P<0.01). The side-effects were mild. Conclusion Middle artificial liver is effective in the treatment of severe hepatitis.
出处
《中国危重病急救医学》
CAS
CSCD
2004年第1期6-8,共3页
Chinese Critical Care Medicine
基金
国家自然科学基金资助项目 ( 3 0 0 2 70 0 1)
关键词
肝炎
重型
血浆置换
人工肝
肝支持
severe hepatitis
plasma exchange
artificial liver
liver support
